Top Penny Stocks To Watch In September 2026

Over the last 7 days, the United States market has risen 1.6%, and over the past year, it is up 14%, with earnings expected to grow by 18% per annum in the coming years. For investors interested in smaller or newer companies, penny stocks—though an outdated term—remain an intriguing investment area due to their potential for significant returns when backed by solid financials. This article will explore three penny stocks that stand out for their financial strength and growth potential, offering a chance to uncover hidden value in quality companies.

Let's dive into some prime choices out of the screener.

MindWalk Holdings (HYFT)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: MindWalk Holdings Corp. is a bio-native AI company with a market capitalization of $69.54 million.

Operations: The company generates revenue from its Antibody Production and Related Services segment, amounting to CA$16.23 million.

Market Cap: $69.54M

MindWalk Holdings Corp., a bio-native AI company, is navigating the complexities of growth with a market cap of US$69.54 million and revenue from its antibody production segment amounting to CA$16.23 million annually. Despite being unprofitable, it has secured a US$30 million credit facility to support biologics programs and expansion efforts. Recent technological advancements in partnership with AMD and Vultr have enhanced its AI capabilities, potentially reducing operational costs. However, challenges remain as the company faces high volatility and less than one year of cash runway if current cash flow trends persist, alongside an inexperienced management team averaging 1.7 years in tenure.

• Take a closer look at MindWalk Holdings' potential here in our financial health report.
• Learn about MindWalk Holdings' future growth trajectory here.

AC Immune (ACIU)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: AC Immune SA is a clinical-stage biopharmaceutical company focused on discovering, designing, and developing medicines and diagnostic products for neurodegenerative diseases related to protein misfolding, with a market cap of $279.39 million.

Operations: The company generates revenue of CHF 17.51 million from its segment dedicated to the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases.

Market Cap: $279.39M

AC Immune SA, with a market cap of $279.39 million, is actively advancing its clinical-stage biopharmaceutical pursuits in neurodegenerative diseases. Recent positive safety and immunogenicity results from its VacSYn Phase 2 trial for ACI-7104 in early-stage Parkinson's disease highlight promising therapeutic potential. Despite being unprofitable, it has reduced losses over the past five years by 7% annually and maintains sufficient cash runway beyond a year. The company remains debt-free but faces challenges with short-term liabilities exceeding assets slightly at CHF93.4M versus CHF100.2M, while an inexperienced management team may impact strategic execution moving forward.

• Click to explore a detailed breakdown of our findings in AC Immune's financial health report.
• Examine AC Immune's earnings growth report to understand how analysts expect it to perform.

Applied Energetics (AERG)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Applied Energetics, Inc. develops, manufactures, and sells advanced high-performance lasers and optical systems, as well as integrated guided energy systems globally, with a market cap of $179.50 million.

Operations: The company's revenue is derived entirely from its Aerospace & Defense segment, totaling $0.24 million.

Market Cap: $179.5M

Applied Energetics, Inc., with a market cap of US$179.50 million, is pre-revenue with sales totaling only US$0.24 million from its Aerospace & Defense segment. The company reported a net loss of US$8.09 million for the first half of 2026, reflecting increasing losses over the past five years at an annual rate of 27.4%. Although it has reduced its debt-to-equity ratio significantly over five years and holds more cash than total debt, Applied Energetics faces financial challenges with less than one year of cash runway and an inexperienced management team averaging 1.8 years in tenure amidst stable volatility levels.

• Jump into the full analysis health report here for a deeper understanding of Applied Energetics.
• Examine Applied Energetics' past performance report to understand how it has performed in prior years.

Where To Now?

• Get an in-depth perspective on all 324 US Penny Stocks by using our screener here.
• Curious About Other Options? This technology could replace computers: discover the 25 stocks are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com